Search

Your search keyword '"Chaix, Marie-Laure"' showing total 940 results
Start Over Author "Chaix, Marie-Laure"
940 results on '"Chaix, Marie-Laure"'

201. Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).

Author

Molina, Jean-Michel, Gallien, Sebastien, Chaix, Marie-Laure, Abbassi, El Mountacer El, Madelaine, Isabelle, Katlama, Christine, Valin, Nadia, Delobel, Pierre, Desseaux, Kristell, and Peytavin, Gilles

Subjects
RITONAVIR, DARUNAVIR, HIV-positive persons, CLINICAL trials, GENETIC mutation
Abstract

Objectives To assess whether low-dose ritonavir-boosted darunavir (darunavir/r) in combination with two NRTIs could maintain virological suppression in patients on a standard regimen of darunavir/r + two NRTIs. Design A multicentre, Phase II, non-comparative, single-arm, open-label study. Setting Tertiary care hospitals in France. Subjects One hundred HIV-1-infected adults with no darunavir or NRTI resistance-associated mutations (RAMs) and a plasma HIV RNA level ≤50 copies/mL for ≥12 months on once-daily darunavir/r (800/100 mg) + two NRTIs for ≥6 months were switched to darunavir/r 400/100 mg with the same NRTIs. Primary outcome measure Proportion of patients with treatment success: plasma HIV RNA level ≤50  copies/mL up to 48 weeks without any change in the study regimen, in a modified ITT (mITT) analysis. Results At baseline, most patients were male (78%), with a median age of 43 years, median duration of HIV RNA ≤50 copies/mL of 35 months and median CD4 T cell count of 633 cells/mm3. Seventy-six percent received tenofovir/emtricitabine and 24% abacavir/lamivudine. Five patients were excluded from the mITT analysis. The rate of treatment success through to week 48 was 91.6% (87/95; 95% CI 84.1%–96.3%). No RAM was detected in three amplifiable genotypes. A total of 212 adverse events (AEs) occurred in 64 patients (64%); 9 AEs were serious, none leading to treatment discontinuation. Conclusions In HIV-infected patients well suppressed with darunavir/r (800/100 mg) and two NRTIs, a reduction of the darunavir dose to 400 mg/day maintained virological efficacy and was safe over 48 weeks. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

202. Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection.

Author

Stefic, Karl, Novelli, Sophie, Mahjoub, Nadia, Seng, Remonie, Molina, Jean-Michel, Cheneau, Christine, Barin, Francis, Chaix, Marie-Laure, Meyer, Laurence, Delaugerre, Constance, and French National Agency for Research on AIDS and Viral Hepatitis (ANRS) PRIMO Study Group

Subjects
DIAGNOSIS of HIV infections, HIV infections, THERAPEUTICS, HIV-positive persons, HIGHLY active antiretroviral therapy, ANTIRETROVIRAL agents
Abstract

We assessed the impact of early antiretroviral treatment (ART) on human immunodeficiency virus (HIV) antibody detection by rapid tests in 44 individuals after several years of successful ART. HIV self-tests and point-of-care tests were negative in 30% and 7%-9% of cases, respectively. These data reinforce the message that patients should never be retested after entering HIV care. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

204. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

Author

Rhee, Soo-Yon, primary, Blanco, Jose Luis, additional, Jordan, Michael R., additional, Taylor, Jonathan, additional, Lemey, Philippe, additional, Varghese, Vici, additional, Hamers, Raph L., additional, Bertagnolio, Silvia, additional, de Wit, Tobias F. Rinke, additional, Aghokeng, Avelin F., additional, Albert, Jan, additional, Avi, Radko, additional, Avila-Rios, Santiago, additional, Bessong, Pascal O., additional, Brooks, James I., additional, Boucher, Charles A. B., additional, Brumme, Zabrina L., additional, Busch, Michael P., additional, Bussmann, Hermann, additional, Chaix, Marie-Laure, additional, Chin, Bum Sik, additional, D’Aquin, Toni T., additional, De Gascun, Cillian F., additional, Derache, Anne, additional, Descamps, Diane, additional, Deshpande, Alaka K., additional, Djoko, Cyrille F., additional, Eshleman, Susan H., additional, Fleury, Herve, additional, Frange, Pierre, additional, Fujisaki, Seiichiro, additional, Harrigan, P. Richard, additional, Hattori, Junko, additional, Holguin, Africa, additional, Hunt, Gillian M., additional, Ichimura, Hiroshi, additional, Kaleebu, Pontiano, additional, Katzenstein, David, additional, Kiertiburanakul, Sasisopin, additional, Kim, Jerome H., additional, Kim, Sung Soon, additional, Li, Yanpeng, additional, Lutsar, Irja, additional, Morris, Lynn, additional, Ndembi, Nicaise, additional, NG, Kee Peng, additional, Paranjape, Ramesh S., additional, Peeters, Martine, additional, Poljak, Mario, additional, Price, Matt A., additional, Ragonnet-Cronin, Manon L., additional, Reyes-Terán, Gustavo, additional, Rolland, Morgane, additional, Sirivichayakul, Sunee, additional, Smith, Davey M., additional, Soares, Marcelo A., additional, Soriano, Vincent V., additional, Ssemwanga, Deogratius, additional, Stanojevic, Maja, additional, Stefani, Mariane A., additional, Sugiura, Wataru, additional, Sungkanuparph, Somnuek, additional, Tanuri, Amilcar, additional, Tee, Kok Keng, additional, Truong, Hong-Ha M., additional, van de Vijver, David A. M. C., additional, Vidal, Nicole, additional, Yang, Chunfu, additional, Yang, Rongge, additional, Yebra, Gonzalo, additional, Ioannidis, John P. A., additional, Vandamme, Anne-Mieke, additional, and Shafer, Robert W., additional

Published
2015
Full Text
View/download PDF

205. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial

Author

Chéret, Antoine, primary, Nembot, Georges, additional, Mélard, Adeline, additional, Lascoux, Caroline, additional, Slama, Laurence, additional, Miailhes, Patrick, additional, Yeni, Patrick, additional, Abel, Sylvie, additional, Avettand-Fenoel, Véronique, additional, Venet, Alain, additional, Chaix, Marie-Laure, additional, Molina, Jean-Michel, additional, Katlama, Christine, additional, Goujard, Cécile, additional, Tamalet, Catherine, additional, Raffi, François, additional, Lafeuillade, Alain, additional, Reynes, Jacques, additional, Ravaux, Isabelle, additional, Hoën, Bruno, additional, Delfraissy, Jean-François, additional, Meyer, Laurence, additional, and Rouzioux, Christine, additional

Published
2015
Full Text
View/download PDF

206. Universal Maternal ART for PMTCT

Author

Becquet , Renaud, Ekouevi , Didier Koumavi, Arrivé , Elise, Stringer , Jeffrey, Meda , Nicolas, Chaix , Marie Laure, Tréluyer , Jean-Marc, Leroy , Valériane, Rouzioux , Christine, Blanche , Stéphane, Dabis , François, Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Programme PAC-CI, ANRS France Recherche Nord & sud Sida-hiv hépatites, Centre for Infectious Disease Research in Zambia (CIDRZ), Centre for Infectious Disease Research, Site ANRS du Burkina Faso, Université Joseph Ki-Zerbo [Ouagadougou] (UJZK), Infections à Vih, Réservoirs, Pharmacologie des Antirétroviraux et Prévention de la Transmission Mère Enfant, Université Paris Descartes - Paris 5 (UPD5), Laboratoire de pharmacologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Virologie [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], ANRS, Institut de Santé Publique, d'Epidémiologie et de Développement ( ISPED ), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre for Infectious Disease Research in Zambia ( CIDRZ ), Université de Ouagadougou, Université Paris Descartes - Paris 5 ( UPD5 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP]

Subjects
MESH: Acquired Immunodeficiency Syndrome, MESH: Humans, MESH: CD4 Lymphocyte Count, MESH : Acquired Immunodeficiency Syndrome, MESH : Humans, virus diseases, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Antiretroviral Therapy, Highly Active, MESH: Antiretroviral Therapy, Highly Active, MESH: Health Resources, MESH: HIV-1, MESH: Infectious Disease Transmission, Vertical, MESH : Pregnancy, MESH: Pregnancy, MESH : Pregnancy Complications, Infectious, MESH: Breast Feeding, MESH : Breast Feeding, MESH : CD4 Lymphocyte Count, MESH : Female, MESH : Health Resources, MESH: Pregnancy Complications, Infectious, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Infectious Disease Transmission, Vertical, MESH: Female, MESH : HIV-1
Abstract

International audience; Prevention of mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) remains a challenge in most resource-limited settings, particularly in Africa. Single-dose and short-course antiretroviral (ARV) regimens are only partially effective and have failed to achieve wide coverage despite their apparent simplicity. More potent ARV combinations are restricted to pregnant women who need treatment for themselves and are also infrequently used. Furthermore, postnatal transmission via breast-feeding is a serious additional threat. Modifications of infant feeding practices aim to reduce HIV-1 transmission through breast milk; replacement feeding is neither affordable nor safe for the majority of African women, and early breast-feeding cessation (eg, prior to 6 months of life) requires substantial care and nutritional counseling to be practiced safely. The recent roll out of ARV treatment has changed the paradigm of prevention of MTCT. To date, postnatal ARV interventions that have been evaluated target either maternal ARV treatment to selected breast-feeding women, with good efficacy, or single-drug postexposure prophylaxis for short periods of time to their neonates, with a partial efficacy and at the expense of acquisition of drug-related viral resistance. We hypothesize that a viable solution to eliminate pediatric AIDS lies in the universal provision of fully suppressive ARV regimens to all HIV-1-infected women through pregnancy, delivery, and the entire breast-feeding period. On the basis of available evidence, we suggest translating into practice the recently available evidence on this matter without any further delay.

Published
2009

207. Reply to Perrella et al

Author

Aaron, Laurent, Lebray, Pascal, Alyanakian, Marie-Alexandra, Roudiere, Laurent, Therby, Audrey, Chaix, Marie-Laure, Dupont, Bertrand, Pol, Stanislas, and Viard, Jean-Paul

Subjects
Hepatitis C virus -- Risk factors, Hepatitis C virus -- Research, T cells -- Research, Health, Health care industry
Published
2005

208. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.

Author

Peytavin, Gilles, Lê, Minh P., Belarbi, Linda, Launay, Odile, Chaix, Marie-Laure, Mahjoub, Nadia, Dulioust, Emmanuel, Salmon, Dominique, Viard, Jean-Paul, Ghosn, Jade, and Duvivier, Claudine

Subjects
ANTIVIRAL agents, MARAVIROC (Drug), RALTEGRAVIR, ANTIRETROVIRAL agents, HIV infection transmission, BODY fluids, CERVIX uteri, COMPARATIVE studies, HETEROCYCLIC compounds, HIV, HIV infections, HYDROCARBONS, LONGITUDINAL method, RESEARCH methodology, MEDICAL cooperation, RESEARCH, SEMEN, VAGINA, VIRAL load, EVALUATION research, ANTI-HIV agents, THERAPEUTICS
Abstract

Background: Sub-optimal penetration of antiretroviral drugs in genital compartments might promote local HIV persistence and increase the risk of HIV transmission.Objectives: To describe the penetration of maraviroc, raltegravir, raltegravir glucuronide and rilpivirine in seminal plasma and cervico-vaginal secretions (CVS) and to assess local antiretroviral efficacy in HIV-1-positive patients.Methods: This was a prospective, multicentre study. Inclusion criteria were HIV-1 positive, age >18 years, receiving regimens containing maraviroc and/or raltegravir and/or rilpivirine for >1 month, and good self-reported adherence. Paired blood and genital samples were collected 12 h (raltegravir and maraviroc) or 24 h (rilpivirine) post-dose. These concentrations were determined (UPLC-MS/MS) in blood and seminal plasma (total and unbound) and CVS (total, dried spots) and HIV-RNA was quantified in paired blood and genital samples.Results: Among the 54 enrolled patients, 15 received maraviroc (6 men), 27 received raltegravir (14 men) and 20 received rilpivirine (10 men), corresponding to 54 total and 52 unbound plasma concentrations, 29 total CVS samples and 23 total and 18 unbound seminal plasma samples. Maraviroc and raltegravir displayed a ratio of genital fluids/plasma concentrations >0.5 in both male and female genital tracts. Conversely, rilpivirine displayed a low ratio. Antiretroviral free fractions were consistent with historical data. Nine patients had blood plasma HIV-RNA >50 copies/mL (2/9 had sub-optimal antiretroviral blood plasma exposure) and two other patients had detectable HIV-RNA in genital fluids.Conclusions: Maraviroc and raltegravir demonstrated good penetration in genital compartments, yielding good local virological response in genital compartments, whereas rilpivirine presented a low penetration profile but good local response. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

209. Assessment of HIV Screening Tests for Use in Preexposure Prophylaxis Programs.

Author

Delaugerre, Constance, Antoni, Guillemette, Mahjoub, Nadia, Pialoux, Gilles, Cua, Eric, Pasquet, Armelle, Hall, Nolwenn, Tremblay, Cécile, Cotte, Laurent, Capitant, Catherine, Chaix, Marie-Laure, Meyer, Laurence, Molina, Jean-Michel, and IPERGAY Study Group

Subjects
DIAGNOSIS of HIV infections, IMMUNOASSAY, ANTIGEN-antibody reactions, VIRAL transmission, DRUG resistance, HIV prevention, COMPARATIVE studies, HIV, RESEARCH methodology, MEDICAL cooperation, MEDICAL screening, PREVENTIVE health services, RESEARCH, RNA, SERODIAGNOSIS, VIRAL antibodies, VIRAL antigens, EVALUATION research, RETROSPECTIVE studies
Abstract

Preexposure prophylaxis programs involve frequent human immunodeficiency virus (HIV) testing. We evaluated the sensitivity of 2 antigen/antibody immunoassays (Architect and Bioplex), 2 antibody-based rapid tests (Vikia-HIV-1/2 and Autotest-VIH), and 1 antigen/antibody rapid test (Alere HIV Combo) for the diagnosis of HIV infection. Among the 31 HIV-1-infected participants in the ANRS-IPERGAY trial, HIV-1 RNA was detected alone in only 2. The sensitivities of the Architect and Bioplex assays were 83% (95% confidence interval [CI], 76%-99%) and 82% (95% CI, 63%-94%), respectively. The sensitivities of the Vikia, Autotest, and Alere tests were 54% (95% CI, 34%-72%), 50% (95% CI, 31%-69%), and 78% (95% CI, 58%-91%), respectively. Antigen/antibody tests should be preferred to avoid missing cases of acute HIV infection and to decrease the related risks of viral transmission and emergence of drug resistance. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

214. Field Evaluation of Dried Blood Spots for Routine HIV-1 Viral Load and Drug Resistance Monitoring in Patients Receiving Antiretroviral Therapy in Africa and Asia

Author

Monleau, Marjorie, primary, Aghokeng, Avelin F., additional, Eymard-Duvernay, Sabrina, additional, Dagnra, Anoumou, additional, Kania, Dramane, additional, Ngo-Giang-Huong, Nicole, additional, Touré-Kane, Coumba, additional, Truong, Lien X. T., additional, Chaix, Marie-Laure, additional, Delaporte, Eric, additional, Ayouba, Ahidjo, additional, and Peeters, Martine, additional

Published
2014
Full Text
View/download PDF

215. Increasing Rate of TAMs and Etravirine Resistance in HIV-1–Infected Adults Between 12 and 24 Months of Treatment

Author

Messou, Eugène, primary, Chaix, Marie-Laure, additional, Gabillard, Delphine, additional, Yapo, Vincent, additional, Toni, Thomas-d’Aquin, additional, Minga, Albert, additional, Kouakou, Martial Guillaume, additional, Ouattara, Eric, additional, Rouzioux, Christine, additional, Danel, Christine, additional, Eholie, Serge P., additional, and Anglaret, Xavier, additional

Published
2013
Full Text
View/download PDF

216. Lopinavir/Ritonavir Monotherapy as a Nucleoside Analogue–Sparing Strategy to Prevent HIV-1 Mother-to-Child Transmission: The ANRS 135 PRIMEVA Phase 2/3 Randomized Trial

Author

Tubiana, Roland, primary, Mandelbrot, Laurent, additional, Le Chenadec, Jérome, additional, Delmas, Sandrine, additional, Rouzioux, Christine, additional, Hirt, Deborah, additional, Treluyer, Jean-Marc, additional, Ekoukou, Dieudonné, additional, Bui, Eda, additional, Chaix, Marie-Laure, additional, Blanche, Stéphane, additional, Warszawski, Josiane, additional, Ngondi, J, additional, Chernai, N, additional, Teglas, JP, additional, Laurent, C, additional, Huyn, P, additional, Le Chenadec, J, additional, Delmas, S, additional, Warszawski, J, additional, Muret, P, additional, Baazia, Y, additional, Jeantils, V, additional, Lachassine, E, additional, Rodrigues, A, additional, Sackho, A, additional, Sagnet-Pham, I, additional, Tassi, S, additional, Breilh, D, additional, Iriard, X, additional, Andre, G, additional, Douard, D, additional, Reigadas, S, additional, Roux, D, additional, Louis, I, additional, Morlat, P, additional, Pedebosq, S, additional, Barre, J, additional, Estrangin, E, additional, Fauveau, E, additional, Garrait, V, additional, Ledudal, P, additional, Pichon, C, additional, Richier, L, additional, Thebault, A, additional, Touboul, C, additional, Bornarel, D, additional, Chambrin, V, additional, Clech, L, additional, Dubreuil, P, additional, Foix L'helias, L, additional, Picone, O, additional, Schoen, H, additional, Stralka, M, additional, Crenn-Hebert, C, additional, Floch-Tudal, C, additional, Hery, E, additional, Ichou, H, additional, Mandelbrot, L, additional, Meier, F, additional, Tournier, V, additional, Walter, S, additional, Chevojon, P, additional, Devidas, A, additional, Granier, M, additional, Khanfar-boudjemai, M, additional, Malbrunot, C, additional, Nguyen, R, additional, Ollivier, B, additional, Radideau, E, additional, Turpault, I, additional, Jault, T, additional, Barrail, A, additional, Colmant, C, additional, Fourcade, C, additional, Goujard, C, additional, Pallier, C, additional, Peretti, D, additional, Taburet, AM, additional, Bocket, L, additional, D'angelo, S, additional, Godart, F, additional, Hammou, Y, additional, Houdret, N, additional, Mazingue, F, additional, Thielemans, B, additional, Brochier, C, additional, Cotte, L, additional, Januel, F, additional, Le Thi, T, additional, Gagneux, MC, additional, Bozio, A, additional, Massardier, J, additional, Kebaïli, K, additional, Ben, Akli K, additional, Heller-Roussin, B, additional, Riehl, C, additional, Roos, S, additional, Taccot, F, additional, Winter, C, additional, Arias, J, additional, Brunet-François, C, additional, Dailly, E, additional, Flet, L, additional, Gournay, V, additional, Mechinaud, F, additional, Reliquet, V, additional, Winner, N, additional, Peytavin, G, additional, Bardin, C, additional, Boudjoudi, N, additional, Compagnucci, A, additional, Guerin, C, additional, Krivine, A, additional, Pannier, E, additional, Salmon, D, additional, Treluyer, JM, additional, Firtion, G, additional, Ayral, D, additional, Ciraru-Vigneron, N, additional, Mazeron, MC, additional, Rizzo Badoin, N, additional, Trout, H, additional, Benachi, A, additional, Boissand, C, additional, Bonnet, D, additional, Boucly, S, additional, Blanche, S, additional, Chaix, ML, additional, Duvivier, C, additional, Parat, S, additional, Cayol, V, additional, Oucherif, S, additional, Rouzioux, C, additional, Viard, JP, additional, Bonmarchand, M, additional, De Montgolfier, I, additional, Dommergues, M, additional, Fievet, MH, additional, Iguertsira, M, additional, Pauchard, M, additional, Quetin, F, additional, Soulie, C, additional, Tubiana, R, additional, Faye, A, additional, Magnier, S, additional, Bui, E, additional, Carbonne, B, additional, Daguenel Nguyen, A, additional, Harchi, N, additional, Meyohas, MC, additional, Poirier, JM, additional, Rodriguez, J, additional, Hervé, F, additional, Pialloux, G, additional, Dehee, A, additional, Dollfus, C, additional, Tillous Borde, I, additional, Vaudre, G, additional, Wallet, A, additional, Allemon, MC, additional, Bolot, P, additional, Boussairi, A, additional, Chaplain, C, additional, Ekoukou, D, additional, Ghibaudo, N, additional, Kana, JM, additional, Khuong, MA, additional, Weil, M, additional, Entz-Werle, N, additional, Livolsi Lutz, P, additional, Beretz, L, additional, Cheneau, M, additional, Partisani, ML, additional, Schmitt, MP, additional, Acar, P, additional, Armand, E, additional, Berrebi, A, additional, Guibaud Plo, C, additional, Lavit, M, additional, Nicot, F, additional, Tricoire, J, additional, Ajana, F, additional, and Huleux, T, additional

Published
2013
Full Text
View/download PDF

219. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

Author

Lortholary, Olivier, Roussillon, Caroline, Boucherie, Céline, Padoin, Christophe, Chaix, Marie-Laure, Breton, Guillaume, Rami, Agathe, Veziris, Nicolas, Patey, Olivier, Caumes, Eric, May, Thierry, Molina, Jean-Michel, Robert, Jérome, Tod, Michel, Fagard, Catherine, Chêne, Geneviève, and ANRS 129 BKVIR Trial Group

Subjects
TUBERCULOSIS treatment, EMTRICITABINE-tenofovir, EFAVIRENZ-emtricitabine-tenofovir (Drug), COMBINATION drug therapy, DRUG tolerance
Abstract

Background: HIV-infected patients with TB need simplified, effective and well-tolerated antiretroviral regimens.Methods: The French ANRS 129 BKVIR open trial evaluated the once-daily tenofovir DF/emtricitabine and efavirenz combination, started within 12 weeks after TB treatment initiation, in antiretroviral-naive HIV-1-infected patients. Success was defined as an HIV-1 RNA <50 copies/mL and TB cure at 48 weeks.Results: TB was confirmed microbiologically (90%) or histologically (10%) in 69 patients (71% male; median age 43 years; 54% born in Africa). The median time between TB treatment initiation and antiretroviral therapy was 8 weeks (range 1-22 weeks). At baseline, median HIV-1 RNA was 5.4 log10 copies/mL and median CD4 cell count 74 cells/mm(3). In the ITT analysis, combined success at week 48 was achieved in 57/69 patients (83%, 95% CI 74-92). Twelve patients did not achieve virological success, and TB was not cured in one of them. Among the 47 patients who fully adhered to the strategy, the success rate was 96% (95% CI 90-100) and was not affected by low rifampicin and isoniazid serum concentrations. Forty-nine serious adverse events were reported in 31 patients (45%), and 11 led to antiretroviral drug interruption. All adverse events resolved. The immune reconstitution inflammatory syndrome occurred in 23 patients (33%, 95% CI 22-44), and was associated with a low baseline BMI (P = 0.03) and a low haemoglobin level (P = 0.02).Conclusion: These results support the use of tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients with TB. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

220. Continuous versus intermittent treatment strategies during primary HIV-1 infection

Author

Goujard, Cécile, primary, Emilie, Dominique, additional, Roussillon, Caroline, additional, Godot, Véronique, additional, Rouzioux, Christine, additional, Venet, Alain, additional, Colin, Céline, additional, Pialoux, Gilles, additional, Girard, Pierre-Marie, additional, Boilet, Valérie, additional, Chaix, Marie-Laure, additional, Galanaud, Pierre, additional, and Chene, Geneviève, additional

Published
2012
Full Text
View/download PDF

222. CCR5 antagonists

Author

Frange, Pierre, primary, Briand, Nelly, additional, Veber, Florence, additional, Moshous, Despina, additional, Avettand-Fenoel, Véronique, additional, Rouzioux, Christine, additional, Blanche, Stéphane, additional, and Chaix, Marie-Laure, additional

Published
2012
Full Text
View/download PDF

228. Genotypic prediction of HIV-1 subtype D tropism

Author

Raymond, Stéphanie, primary, Delobel, Pierre, additional, Chaix, Marie-Laure, additional, Cazabat, Michelle, additional, Encinas, Stéphanie, additional, Bruel, Patrick, additional, Sandres-Sauné, Karine, additional, Marchou, Bruno, additional, Massip, Patrice, additional, and Izopet, Jacques, additional

Published
2011
Full Text
View/download PDF

230. Association Between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1–Infected Adults on Antiretroviral Therapy in Côte d'Ivoire

Author

Messou, Eugène, primary, Chaix, Marie-Laure, additional, Gabillard, Delphine, additional, Minga, Albert, additional, Losina, Elena, additional, Yapo, Vincent, additional, Kouakou, Martial, additional, Danel, Christine, additional, Sloan, Caroline, additional, Rouzioux, Christine, additional, Freedberg, Kenneth A, additional, and Anglaret, Xavier, additional

Published
2011
Full Text
View/download PDF

231. Interpretation of Real-Time PCR Results for Hepatitis C Virus RNA When Viral Load Is Below Quantification Limits

Author

Laperche, Syria, primary, Bouchardeau, Françoise, additional, André-Garnier, Elisabeth, additional, Thibault, Vincent, additional, Roque-Afonso, Anne-Marie, additional, Trimoulet, Pascale, additional, Colimon, Ronald, additional, Duverlie, Gilles, additional, Leguillou-Guillemette, Hélène, additional, Lunel, Françoise, additional, Bouvier-Alias, Magali, additional, Pawlotsky, Jean-Michel, additional, Henquell, Cécile, additional, Schvoerer, Evelyne, additional, Stoll-Keller, Françoise, additional, Chaix, Marie-Laure, additional, Branger, Michel, additional, Gaudy-Graffin, Catherine, additional, Rosenberg, Arielle R., additional, Pozzetto, Bruno, additional, Vallet, Sophie, additional, Baazia, Yazid, additional, Izopet, Jacques, additional, and Lefrère, Jean-Jacques, additional

Published
2011
Full Text
View/download PDF

232. Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: An ANRS AC12 working group study

Author

Nouhin, Janin, primary, Donchai, Tawee, additional, Hoang, Khanh Thu Huynh, additional, Ken, Sreymom, additional, Kamkorn, Jiraporn, additional, Tran, Ton, additional, Ayouba, Ahidjo, additional, Peeters, Martine, additional, Chaix, Marie-Laure, additional, and Lien, Truong Xuan, additional

Published
2011
Full Text
View/download PDF

233. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: The HEPAIG study

Author

Piroth, Lionel, primary, Larsen, Christine, additional, Binquet, Christine, additional, Alric, Laurent, additional, Auperin, Isabelle, additional, Chaix, Marie-Laure, additional, Dominguez, Stéphanie, additional, Duval, Xavier, additional, Gervais, Anne, additional, Ghosn, Jade, additional, Delarocque-Astagneau, Elisabeth, additional, and Pol, Stanislas, additional

Published
2010
Full Text
View/download PDF

237. Short Communication: Evidence of HIV Type 1 Complex and Second Generation Recombinant Strains Among Patients Infected in 1997–2007 in France: ANRS CO06 PRIMO Cohort

Author

Galimand, Julie, primary, Frange, Pierre, additional, Rouzioux, Christine, additional, Deveau, Christiane, additional, Avettand-Fenoël, Véronique, additional, Ghosn, Jade, additional, Lascoux, Caroline, additional, Goujard, Cécile, additional, Meyer, Laurence, additional, and Chaix, Marie-Laure, additional

Published
2010
Full Text
View/download PDF

240. Universal Antiretroviral Therapy for Pregnant and Breast‐Feeding HIV‐1–Infected Women: Towards the Elimination of Mother‐to‐Child Transmission of HIV‐1 in Resource‐Limited Settings

Author

Becquet, Renaud, primary, Ekouevi, Didier K., additional, Arrive, Elise, additional, Stringer, Jeffrey S. A., additional, Meda, Nicolas, additional, Chaix, Marie‐Laure, additional, Treluyer, Jean‐Marc, additional, Leroy, Valériane, additional, Rouzioux, Christine, additional, Blanche, Stéphane, additional, and Dabis, François, additional

Published
2009
Full Text
View/download PDF

242. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

Author

Legrand-Abravanel, Florence, primary, Colson, Philippe, additional, Leguillou-Guillemette, Hélène, additional, Alric, Laurent, additional, Ravaux, Isabelle, additional, Lunel-Fabiani, Françoise, additional, Bouviers-Alias, Magali, additional, Trimoulet, Pascale, additional, Chaix, Marie Laure, additional, Hézode, Christophe, additional, Foucher, Juliette, additional, Fontaine, Hélène, additional, Roque-Afonso, Anne-Marie, additional, Gassin, Michèle, additional, Schvoerer, Evelyne, additional, Gaudy, Catherine, additional, Roche, Bruno, additional, Doffoël, Michel, additional, D'Alteroche, Louis, additional, Vallet, Sophie, additional, Baazia, Yazid, additional, Pozzetto, Bruno, additional, Thibault, Vincent, additional, Nousbaum, Jean-Baptiste, additional, Roulot, Dominique, additional, Coppere, Henry, additional, Poinard, Thierry, additional, Payan, Christopher, additional, and Izopet, Jacques, additional

Published
2009
Full Text
View/download PDF

244. Low Prevalence of HIV Type 1 Drug Resistance Mutations in Untreated, Recently Infected Patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: The ANRS 12134 Study

Author

Ayouba, Ahidjo, primary, Lien, Truong T.X., additional, Nouhin, Janin, additional, Vergne, Laurence, additional, Aghokeng, Avelin Fobang, additional, Ngo-Giang-Huong, Nicole, additional, Diop, Halimatou, additional, Kane, Coumba Touré, additional, Valéa, Diane, additional, Rouet, François, additional, Joulia-Ekaza, Dominique, additional, Toni, Thomas D'Aquin, additional, Nerrienet, Eric, additional, Ngole, Eitel Mpoudi, additional, Delaporte, Eric, additional, Costagliola, Dominique, additional, Peeters, Martine, additional, and Chaix, Marie-Laure, additional

Published
2009
Full Text
View/download PDF

245. Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells

Author

Lécuroux, Camille, primary, Girault, Isabelle, additional, Boutboul, François, additional, Urrutia, Alejandra, additional, Goujard, Cécile, additional, Meyer, Laurence, additional, Lambotte, Olivier, additional, Chaix, Marie-Laure, additional, Martinez, Valérie, additional, Autran, Brigitte, additional, Sinet, Martine, additional, and Venet, Alain, additional

Published
2009
Full Text
View/download PDF

247. Medium-Term Probability of Success of Antiretroviral Treatment after Early Warning Signs of Treatment Failure in West African Adults

Author

Danel, Christine, primary, Gabillard, Delphine, additional, Inwoley, Andre, additional, Chaix, Marie Laure, additional, Toni, Thomas D'aquin, additional, Moh, Raoul, additional, Messou, Eugene, additional, Bissagnene, Emmanuel, additional, Salamon, Roger, additional, Eholie, Serge, additional, and Anglaret, Xavier, additional

Published
2009
Full Text
View/download PDF

248. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients

Author

Viard, Jean-Paul, primary, Fagard, Catherine, additional, Chaix, Marie-Laure, additional, Rouzioux, Christine, additional, Bouteloup, Vincent, additional, Bentata, Michelle, additional, de Verdière, Nathalie Colin, additional, Pahlavan, Golriz, additional, Weiss, Laurence, additional, Lévy, Yves, additional, and Chêne, Geneviève, additional

Published
2009
Full Text
View/download PDF

249. Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy

Author

Delaugerre, Constance, primary, Flandre, Philippe, additional, Chaix, Marie Laure, additional, Ghosn, Jade, additional, Raffi, François, additional, Dellamonica, Pierre, additional, Jaeger, H., additional, Shürmann, D., additional, Cohen-Codar, Isabelle, additional, Ngo Van, Philippe, additional, Norton, Michael, additional, Taburet, Anne-Marie, additional, Delfraissy, Jean-François, additional, and Rouzioux, Christine, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results